Analysis of Early Progression in Advanced Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab
Treatment with NIVO + IPI in patients with aRCC who have a poor PS or bone metastases may be linked to a high risk of EDP.
Authors
- Tasuku Hiroshige (ORCID: https://orcid.org/0000-0002-0179-2383)
- Makoto Nakiri (ORCID: https://orcid.org/0000-0002-5595-7075)
- Katsuaki Chikui (ORCID: https://orcid.org/0000-0001-7176-2350)
- Keiichiro Uemura (ORCID: https://orcid.org/0000-0002-8239-6066)
- Kouta Watanabe
- Kousuke Ueda (ORCID: https://orcid.org/0000-0002-8154-6616)
- Naoki Ito (ORCID: https://orcid.org/0000-0002-1884-8494)
- Shigetaka Suekane (ORCID: https://orcid.org/0000-0003-1150-2893)
- Kiyoaki Nishihara (ORCID: https://orcid.org/0000-0002-1298-3273)
- Hiroki Suekane
- Satoshi Ohnishi (ORCID: https://orcid.org/0000-0002-2905-8180)
- Tsukasa Igawa (ORCID: https://orcid.org/0000-0002-4359-4473)
Institutions
- Kurume University (JP)
Publication Details
- Journal
- Cancer Diagnosis & Prognosis
- Published
- 2025-05-03
- DOI
- https://doi.org/10.21873/cdp.10446
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52